A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Eisai Europe’s headquarters were expanded to become Eisai Europe, Middle East, Africa and Russia in March 2012. Gary joined Eisai in 2008 as European Commercial Development Director.

Eisai Inc. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research ...

Eisai Alzheimer's drug and clot buster seen as cause of brain hemorrhage death -analysis By Deena Beasley January 4, 20232:03 PM PSTUpdated January 4, 2023 ...

Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024.